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Objectives: Asymptomatic Peripheral Arterial Disease (PAD) is associated with 
greater risk of acute cardiovascular events. American heart association and American 
college of cardiology clinical practice guidelines recommend low dose aspirin to 
reduce the cardiovascular events and mortality in PAD patients. As asymptomatic 
PAD often remains undiagnosed, opportunities for secondary prevention are missed 
in primary care. Therefore, there is a clinical need of early detection of asympto-
matic PAD and to initiate the appropriate preventive treatment. United States pre-
ventive services task force’s recommendation against screening is heavily criticized 
and expansion of the evidence base for PAD screening is recommended in 2011 in 
a focussed update of the guidelines. This study aims to determine the value of PAD 
screening using ankle brachial index test in high risk individuals using decision 
analytic modelling. MethOds: A Markov model was developed to evaluate the cost 
effectiveness of selective PAD screening in high risk individuals followed by preventive 
treatment compared to no screening and no preventive treatment. The analysis was 
conducted from the societal perspective using a lifetime time horizon. To address the 
parameter uncertainty, probabilistic sensitivity analysis was performed. Results: 
Screening and preventive treatment of identified PAD patients with low dose aspirin 
is a dominant strategy producing higher mean quality adjusted life years per patient 
for a lower lifetime cost. The cost effectiveness acceptability curves show that 100% 
simulations favour screening followed by preventive treatment at a willingness to 
pay threshold of 400 Euros. cOnclusiOns: This decision analysis suggests that the 
targeted screening and secondary prevention of cardiovascular events in the identi-
fied patients, is a highly cost effective public health intervention. This study results 
may provide one of the building blocks of evidence expansion for advocating PAD 
screening and to promote its more widespread use to detect and treat PAD patients.
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Objectives: Therapy persistence is important to achieve optimal clinical benefits 
of statin therapy. The aim of this study was to determine the cost-effectiveness 
of pharmaceutical care in community pharmacies, aimed to increase persistence 
with statin therapy for both primary and secondary prevention of cardiovascular 
events (CVEs). MethOds: The effectiveness of the Dutch pharmaceutical care pro-
gram MeMO on improving statin therapy persistence was measured in 500 patients 
and compared to 502 control patients. Time-investments of the program were also 
collected. Markov models with lifelong time-horizons were developed to estimate 
the influence of the program on CVEs: stroke, myocardial infarction (MI), revascu-
larization and mortality. The efficacy of statins, taken from large clinical trials in 
primary and secondary prevention, were adjusted for therapy persistence. A Dutch 
health care provider’s perspective was adopted for the analysis and probabilistic 
sensitivity analyses were performed. Results: Patients in the MeMO program had 
a lower risk for non-persistence, RR = 0.50 (0.40-0.63), the effect was similar in 
primary and secondary prevention. In a cohort of 1,000 patients, 60% of whom had 
a history of CVE, the MeMO program resulted in a reduction of 8 non-fatal strokes, 
2 fatal strokes, 16 non-fatal MIs, 7 fatal MIs and 14 revascularizations. Additional 
medication, disease management and intervention costs in the MeMO program 
were € 375,000; the cost-savings due to reduced CVEs were € 450,000. Thus, the MeMO 
program resulted in 83 quality-adjusted life-years (QALYs) gained and cost-savings 
of € 75,000. Clinical benefits and cost-savings were highest in the secondary preven-
tion population. cOnclusiOns: Pharmaceutical care in community pharmacies 
can improve statin therapy persistence, resulting in more optimal prevention of 
CVEs. The MeMO program resulted in considerable clinical benefits and overall 
cost-savings. Persistence and adherence improving programs in community phar-
macies may provide good value for money and health care insurers should consider 
reimbursing these activities in The Netherlands.
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Objectives: To estimate cost-effectiveness of ivabradine used in treatment of 
chronic heart failure in Poland, using model based on individual patient data from 
pivotal SHIFT trial adapted using contemporary real-life epidemiology, treatment 
pattern and cost country-specific data. MethOds: Economic model based on SHIFT 
trial was originally developed for the UK setting and published. Based on the model, 
in November 2012 NICE gave its positive guidance for the analysed technology in 
line with EMA registered indication, acknowledging a range of conservative assump-
tions. Current study utilizes the NICE model populated with most recently published 
local data. General mortality was estimated from Polish life tables for the year 
2010. Unit cost and expected rate of hospitalizations on standard treatment was 
based on publication in Polish Heart Journal. Standard treatment cost was based 
on official listing of reimbursed drugs. Average cost of ivabradine (5mg and 7.5mg, 
56 tabs) was based on popular drug database (Kamsoft, April 2013). Exchange rate 
of National Bank of Poland 1 EUR= 4.1759 PLN was applied (May 2013). Results: 
At current pharmacy price (55.60 EUR / 56 tabs), incremental cost-utility ratio for 
ivabradine on top of standard treatment vs standard treatment alone is estimated 
at 10 230 EUR / QALY, well below the official cost-effectiveness threshold defined at 
3*DGP per capita (25 336 EUR). Sensitivity analysis revealed that in order to exceed 
the cost-effectiveness threshold, price would have to be increased to 113.60 EUR 
(+104%). cOnclusiOns: Conservative analysis shows that ivabradine used on top 
of standard treatment (ACE inhibitor, beta-blocker, MR antagonist, ±diuretics) in 
trolled with ≥ 3 different classes of antihypertensive therapy). Catheter-based renal 
denervation (RDN) is a novel, minimally invasive therapy for treatment-resistant 
hypertension. The aim of this study was to assess the cost-utility of RDN as compared 
to current standard of care (SoC) for refractory hypertension in Belgium. MethOds: 
A lifetime state-transition, Markov model was used, with health-states encompass-
ing possible long-term consequences of hypertension: stroke, myocardial infarction, 
angina, heart failure, end-stage renal disease. Risk equations were used to calculate 
the risk of events with changing systolic blood pressure (SBP). Reductions in SBP 
following RDN vs. SoC pertain to the results of the Symplicity HTN-2 randomized 
controlled trial. The underlying modeled cohort was defined similar to the same trial: 
mean baseline SBP 178 mmHg, mean age 58 years, 34% with diabetes mellitus. Costs 
pertained to published economic evaluations or public tariffs and reflected the Belgian 
payer perspective. Costs and health outcomes were discounted at a rate of 3%, and 
1.5% respectively. Results: Projected lifetime costs were 21,743€ and 24,558€ in the 
SoC and RDN arms respectively, while total projected life years were 16.43 and 17.23. 
RDN increased patients’ quality of life with 0.93 quality-adjusted life years (QALYs) vs. 
SoC. This resulted in an incremental cost-utility ratio (ICUR) of 3,020€ /QALY. Results 
were most sensitive to changes in SBP reductions, and the cost of RDN procedure, but 
remained under a willingness to pay (WTP) threshold of 20,000€ /QALY. Probabilistic 
sensitivity analyses showed acceptable cost-effectiveness in 100% of cases, under a 
WTP threshold of 20,000€ /QALY. cOnclusiOns: Results of these analyses suggest 
that, under the current model settings, catheter-based RDN procedure could be a 
cost-effective strategy for resistant hypertension in Belgium.
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Objectives: To assess the impact of atorvastatin compared to simvastatin use in the 
Czech Republic on cardiovascular diseases (CVD), Life-Years Gained (LYG) and Quality-
Adjusted Life Years (QALY), based on the real proportional consumption of both statins 
in particular strengths (10 mg, 20 mg, 40 mg). MethOds: Life-time cost-effectiveness 
Markov cohort model was developed with 1 year cycle length and 5 health sates, i.e. 
Alive without CVD, Alive with experience of CVD, Non-fatal CVD, Fatal CVD and Death. 
The probability of transition among health states were derived from Framingham 
equations or from SCORE equations (probability of the first non/fatal CVD), Czech 
life-tables (background mortality) and international cohort studies (probability of 
subsequent CVD). Patients enter the model with base-line risk characteristics: age, 
proportions of males, diabetics, smokers, level of systolic blood pressure and choles-
terol (total and HDL) level. The efficacy data for particular statin and its strength were 
derived from latest meta-analyses. Drug acquisition costs of atorvastatin 10 mg and 
20 mg were 10% higher compared to simvastatin 20 mg and 40 mg. The costs of fatal, 
non-fatal CVD and one-year follow-up after CVD were 1,410 EUR, 1,460 EUR and 580 
EUR. Probabilistic sensitivity analysis (PSA) using a willingness to pay (WTP) threshold 
equal to 1 times GDP per capita (14,300 EUR) was applied. Results: Over a life-time 
horizon, atorvastatin compared to simvastatin provides 8.14 QALYs vs. 8.07 QALYs, 
11.33 LYG vs. 11,24 LYG, 44.8% vs. 46.3% of non-fatal CVD and 28.2% vs. 29.4% of fatal 
CVD. The increment of total costs was 330 EUR for atorvastatin, ICER for atorvastatin 
vs. simvastatin was then 4,720 EUR/ QALY. cOnclusiOns: The use of atorvastatin 
generates 0.07 QALYs more compared to simvastatin per patient in the Czech Republic. 
There is a 98.5% probability of atorvastatin being cost-effective at the selected WTP.
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Objectives: The decision on whether to use more expensive novel oral antico-
agulants (NOACs) or invest resources for quality improvement of warfarin therapy 
requires inputs of both clinical and economic outcome analyses. Outcomes of NOACs 
comparing to warfarin therapy at various levels of patient-time in therapeutic range 
(TTR) in patients with atrial fibrillation were examined from health care provider’s 
perspective. MethOds: A Markov model was designed to compare life-long eco-
nomic and treatment outcomes of warfarin and NOACs in a hypothetical cohort of 
65-year-old atrial fibrillation patients with CHADS2score 2 or above. Model inputs were 
derived from clinical trials published in literature. Outcome measure was incremental 
cost per quality-adjusted life-year (QALY) gained (ICER). Results: Expected cost and 
QALYs of NOACs were USD96,602 and 9.957, correspondingly, in base-case analysis. 
Using USD50,000 as the threshold of willingness-to-pay per QALY, NOACs therapy was 
cost-effective when TTR of warfarin therapy was 60%, or monthly cost of warfarin 
management increased by 1.5-fold or above to achieve 70% TTR. Warfarin therapy 
was cost-effective when TTR of warfarin was 70% with no increment in monthly cost 
of care, or when TTR reached 75% with monthly cost of warfarin care increased up 
to 2.5-fold. At TTR 60%, 70% and 75%, NOACs was cost-effective when monthly drug 
cost was < USD208, < USD135-200 and < USD96-160, respectively. 10,000 Monte Carlo 
simulations showed NOACs to be cost-effective in 77.2%, 52.7% and 31.7% of time at 
TTR of 60%, 70% and 75%, respectively. cOnclusiOns: Acceptance of NOACs as cost-
effective was highly depended upon drug cost, anticoagulation control for warfarin, 
and anticoagulation service cost.
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